Recursion Pharmaceuticals (NASDAQ:RXRX) Sets New 1-Year Low – Time to Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares hit a new 52-week low on Monday . The company traded as low as $5.19 and last traded at $5.34, with a volume of 4151746 shares changing hands. The stock had previously closed at $5.81.

Analysts Set New Price Targets

RXRX has been the topic of a number of research analyst reports. KeyCorp dropped their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Leerink Partners dropped their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Friday, February 28th. Cowen reaffirmed a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, Needham & Company LLC reissued a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $8.25.

Recursion Pharmaceuticals Trading Down 3.8 %

The company has a market capitalization of $2.05 billion, a PE ratio of -3.33 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The company’s fifty day moving average is $7.38 and its 200-day moving average is $6.99.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same period in the previous year, the firm posted ($0.42) earnings per share. The company’s revenue was down 57.8% on a year-over-year basis. On average, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Intech Investment Management LLC acquired a new stake in Recursion Pharmaceuticals in the third quarter valued at approximately $349,000. Charles Schwab Investment Management Inc. boosted its position in shares of Recursion Pharmaceuticals by 17.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock worth $12,789,000 after purchasing an additional 288,926 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Recursion Pharmaceuticals by 11.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 124,654 shares of the company’s stock worth $821,000 after purchasing an additional 13,041 shares in the last quarter. FMR LLC grew its stake in Recursion Pharmaceuticals by 2.1% during the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company’s stock worth $55,116,000 after buying an additional 170,810 shares during the last quarter. Finally, MetLife Investment Management LLC increased its position in Recursion Pharmaceuticals by 13.7% during the 3rd quarter. MetLife Investment Management LLC now owns 136,541 shares of the company’s stock valued at $900,000 after buying an additional 16,405 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.